Andros Pharmaceuticals Co (ROCO:6917) Debt-to-EBITDA : -0.34 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Andros Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$5.10 Mil. Andros Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$22.02 Mil. Andros Pharmaceuticals Co's annualized EBITDA for the quarter that ended in Dec. 2023 was NT$-80.85 Mil. Andros Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.34.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Andros Pharmaceuticals Co's Debt-to-EBITDA or its related term are showing as below:

ROCO:6917' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.39 Med: -0.92 Max: -0.44
Current: -0.44

During the past 5 years, the highest Debt-to-EBITDA Ratio of Andros Pharmaceuticals Co was -0.44. The lowest was -1.39. And the median was -0.92.

ROCO:6917's Debt-to-EBITDA is ranked worse than
100% of 275 companies
in the Biotechnology industry
Industry Median: 1.36 vs ROCO:6917: -0.44

Andros Pharmaceuticals Co Debt-to-EBITDA Historical Data

The historical data trend for Andros Pharmaceuticals Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Debt-to-EBITDA Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.92

-1.39

-1.16

-0.91

-0.44

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-1.01	-1.08	-0.83	-0.70	-0.34

Competitive Comparison of Andros Pharmaceuticals Co's Debt-to-EBITDA

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Debt-to-EBITDA falls into.

Andros Pharmaceuticals Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Andros Pharmaceuticals Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(5.097	+	22.024)	/	-61.5
	=	-0.44

Andros Pharmaceuticals Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(5.097	+	22.024)	/	-80.846
	=	-0.34

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Andros Pharmaceuticals Co (ROCO:6917) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Andros Pharmaceuticals Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines